Journal
CHEST
Volume 139, Issue 1, Pages 190-193Publisher
ELSEVIER SCIENCE BV
DOI: 10.1378/chest.10-0128
Keywords
-
Categories
Funding
- GlaxoSmithKline (GSK)
- AstraZeneca
- Nycomed
- Dutch Asthma Foundation
- Zorg Onderzoek Nederland Medische Wetenschappen
Ask authors/readers for more resources
It is now well recognized that treatment with anti-IgE antibodies like omalizumab is a valuable option in patients with allergic asthma who remain symptomatic despite optimal treatment. To our knowledge, treatment with omalizumab in patients with nonallergic asthma has not been reported. We present and discuss a patient with severe asthma and elevated total IgE who had a negative radioallergosorbent (RAST) test result and a negative skin-prick test result; the patient showed a dramatic improvement with this treatment strategy. CHEST 2011; 139(1):190-193
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available